X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with JUBILANT LIFE SCIENCES - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs JUBILANT LIFE SCIENCES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA JUBILANT LIFE SCIENCES AJANTA PHARMA/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 28.9 26.2 110.2% View Chart
P/BV x 11.9 5.4 221.3% View Chart
Dividend Yield % 0.5 0.3 149.1%  

Financials

 AJANTA PHARMA   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
JUBILANT LIFE SCIENCES
Mar-14
AJANTA PHARMA/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs1,720187 920.8%   
Low Rs1,10365 1,694.3%   
Sales per share (Unadj.) Rs194.6364.3 53.4%  
Earnings per share (Unadj.) Rs45.26.8 660.5%  
Cash flow per share (Unadj.) Rs50.324.5 205.3%  
Dividends per share (Unadj.) Rs8.003.00 266.7%  
Dividend yield (eoy) %0.62.4 23.8%  
Book value per share (Unadj.) Rs132.0164.9 80.1%  
Shares outstanding (eoy) m88.77159.28 55.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.30.3 2,098.2%   
Avg P/E ratio x31.218.4 169.7%  
P/CF ratio (eoy) x28.15.1 545.9%  
Price / Book Value ratio x10.70.8 1,399.6%  
Dividend payout %17.743.8 40.4%   
Avg Mkt Cap Rs m125,29920,061 624.6%   
No. of employees `000NA6.2 0.0%   
Total wages/salary Rs m2,57011,052 23.3%   
Avg. sales/employee Rs ThNM9,383.0-  
Avg. wages/employee Rs ThNM1,786.9-  
Avg. net profit/employee Rs ThNM176.3-  
INCOME DATA
Net Sales Rs m17,27558,034 29.8%  
Other income Rs m166191 87.3%   
Total revenues Rs m17,44258,224 30.0%   
Gross profit Rs m5,8075,786 100.4%  
Depreciation Rs m4512,812 16.0%   
Interest Rs m493,237 1.5%   
Profit before tax Rs m5,474-72 -7,592.2%   
Minority Interest Rs m0-286 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m02,145 0.0%   
Tax Rs m1,460696 209.6%   
Profit after tax Rs m4,0141,090 368.1%  
Gross profit margin %33.610.0 337.2%  
Effective tax rate %26.7-965.9 -2.8%   
Net profit margin %23.21.9 1,236.7%  
BALANCE SHEET DATA
Current assets Rs m7,63929,280 26.1%   
Current liabilities Rs m2,71538,912 7.0%   
Net working cap to sales %28.5-16.6 -171.7%  
Current ratio x2.80.8 373.9%  
Inventory Days Days4384 51.2%  
Debtors Days Days7951 155.2%  
Net fixed assets Rs m6,91455,712 12.4%   
Share capital Rs m177155 114.5%   
"Free" reserves Rs m11,44220,968 54.6%   
Net worth Rs m11,72126,265 44.6%   
Long term debt Rs m14917,169 0.9%   
Total assets Rs m14,81488,606 16.7%  
Interest coverage x112.91.0 11,551.6%   
Debt to equity ratio x00.7 1.9%  
Sales to assets ratio x1.20.7 178.0%   
Return on assets %27.44.9 561.5%  
Return on equity %34.24.2 825.0%  
Return on capital %46.511.6 402.3%  
Exports to sales %55.137.8 145.9%   
Imports to sales %6.016.5 36.4%   
Exports (fob) Rs m9,52721,933 43.4%   
Imports (cif) Rs m1,0389,567 10.8%   
Fx inflow Rs m10,42222,004 47.4%   
Fx outflow Rs m1,67811,749 14.3%   
Net fx Rs m8,74410,255 85.3%   
CASH FLOW
From Operations Rs m3,2648,026 40.7%  
From Investments Rs m-2,093-1,744 120.0%  
From Financial Activity Rs m-1,186-4,447 26.7%  
Net Cashflow Rs m-151,834 -0.8%  

Share Holding

Indian Promoters % 73.8 45.6 161.8%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 1.6 8.7 17.8%  
FIIs % 7.6 21.2 35.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 21.1 80.6%  
Shareholders   20,968 23,815 88.0%  
Pledged promoter(s) holding % 4.4 15.9 27.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   AUROBINDO PHARMA  MERCK LTD  NOVARTIS  FULFORD INDIA  ORCHID PHARMA LTD  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty at Record Close Yet Again; IT & Realty Stocks Rally(Closing)

Indian share markets extended rally in the final hour of the trade, hitting fresh record highs while the Bank nifty touched 27,000 level for the first time. At the closing bell.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jan 22, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS